Literature DB >> 20472486

The genetic basis of hyperuricaemia and gout.

Tony R Merriman1, Nicola Dalbeth.   

Abstract

Gout results from elevated urate concentrations in the blood (hyperuricaemia). When super-saturation of urate is reached, monosodium urate crystals form within the joint. In some individuals, these crystals elicit a painful self-limiting inflammatory response that is characteristic of acute gouty arthritis. The most important cause of hyperuricaemia is reduced excretion of uric acid in the urine. Uric acid excretion is coordinated by a suite of urate transport molecules expressed in the renal collecting tubules, and is a key physiological checkpoint in gout. Other checkpoints in gout are hepatic production of urate, monosodium urate crystal formation, and initiation of the acute inflammatory response. Genome-wide association scans for genes regulating serum urate concentrations have identified two major regulators of hyperuricaemia- the renal urate transporters SLC2A9 and ABCG2. The risk variants at each gene approximately double the risk for gout in people of Caucasian ancestry, with SLC2A9 also resulting in higher risk for gout in people of Polynesian ancestry, a diverse population characterized by a high prevalence of gout. Ongoing genetic association studies are identifying and confirming other genes controlling serum urate concentrations; although genome-wide association studies in gout per se await recruitment of suitable case sample sets. Copyright Â
© 2010 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20472486     DOI: 10.1016/j.jbspin.2010.02.027

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  37 in total

1.  No evidence for association of Chr 9p21 variant rs1333049 with gout in New Zealand case-control sample sets.

Authors:  Angela Hsu; Nicola Dalbeth; Peter Gow; Andrew Harrison; John Highton; Peter B Jones; Lisa K Stamp; Tony R Merriman
Journal:  Rheumatology (Oxford)       Date:  2012-03-06       Impact factor: 7.580

2.  Wearable salivary uric acid mouthguard biosensor with integrated wireless electronics.

Authors:  Jayoung Kim; Somayeh Imani; William R de Araujo; Julian Warchall; Gabriela Valdés-Ramírez; Thiago R L C Paixão; Patrick P Mercier; Joseph Wang
Journal:  Biosens Bioelectron       Date:  2015-08-01       Impact factor: 10.618

3.  Association between SLC2A9 transporter gene variants and uric acid phenotypes in African American and white families.

Authors:  Andrew D Rule; Mariza de Andrade; Martha Matsumoto; Tom H Mosley; Sharon Kardia; Stephen T Turner
Journal:  Rheumatology (Oxford)       Date:  2010-12-24       Impact factor: 7.580

Review 4.  Effects of dairy intake on hyperuricemia and gout.

Authors:  Nicola Dalbeth; Kate Palmano
Journal:  Curr Rheumatol Rep       Date:  2011-04       Impact factor: 4.592

5.  Uric acid: a modulator of prostate cells and activin sensitivity.

Authors:  Febbie Sangkop; Geeta Singh; Ely Rodrigues; Elspeth Gold; Andrew Bahn
Journal:  Mol Cell Biochem       Date:  2016-02-24       Impact factor: 3.396

Review 6.  Genetics of hyperuricemia and gout: implications for the present and future.

Authors:  Ronald L George; Robert T Keenan
Journal:  Curr Rheumatol Rep       Date:  2013-02       Impact factor: 4.592

Review 7.  Impaired response or insufficient dosage? Examining the potential causes of "inadequate response" to allopurinol in the treatment of gout.

Authors:  Lisa K Stamp; Tony R Merriman; Murray L Barclay; Jasvinder A Singh; Rebecca L Roberts; Daniel F B Wright; Nicola Dalbeth
Journal:  Semin Arthritis Rheum       Date:  2014-05-09       Impact factor: 5.532

8.  Additive composite ABCG2, SLC2A9 and SLC22A12 scores of high-risk alleles with alcohol use modulate gout risk.

Authors:  Hung-Pin Tu; Chia-Min Chung; Albert Min-Shan Ko; Su-Shin Lee; Han-Ming Lai; Chien-Hung Lee; Chung-Ming Huang; Chiu-Shong Liu; Ying-Chin Ko
Journal:  J Hum Genet       Date:  2016-05-26       Impact factor: 3.172

9.  Variants of ALPK1 with ABCG2, SLC2A9, and SLC22A12 increased the positive predictive value for gout.

Authors:  Hung-Pin Tu; Albert Min-Shan Ko; Su-Shin Lee; Chi-Pin Lee; Tzer-Min Kuo; Chung-Ming Huang; Ying-Chin Ko
Journal:  J Hum Genet       Date:  2017-11-08       Impact factor: 3.172

10.  Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.

Authors:  M S Hershfield; J T Callaghan; W Tassaneeyakul; T Mushiroda; C F Thorn; T E Klein; M T M Lee
Journal:  Clin Pharmacol Ther       Date:  2012-10-17       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.